1 Study Matches
Exploratory Trial of Ruxolitinib 1.5% Cream for Early Stage Hidradenitis Suppurativa
Explore all stages of Hidradenitis Suppurativa with a topical medication.
18 year(s) or older
Inclusion Criteria:Must have diagnosis of HS for at least 3 months (90 days)
Must have active HS in at least 1 area
Must have negative TB screening assessment
Certain medications can be continued if on stable dose; study coordinator will discuss further.
Exclusion Criteria:Any other active skin disease or condition that may interfere with assessment of HS
Pregnant (or considering becoming pregnant) or lactating females
Does not have reliable internet access for weekly electronic surveys